Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
350
Employees350
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
350
Employees350

HALO Key Statistics

Market cap
9.53B
Market cap9.53B
Price-Earnings ratio
16.70
Price-Earnings ratio16.70
Dividend yield
Dividend yield
Average volume
2.17M
Average volume2.17M
High today
$81.51
High today$81.51
Low today
$79.17
Low today$79.17
Open price
$79.75
Open price$79.75
Volume
620.98K
Volume620.98K
52 Week high
$82.22
52 Week high$82.22
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

With a market cap of 9.53B, Halozyme Therapeutics(HALO) trades at $81.01. The stock has a price-to-earnings ratio of 16.70.

On 2026-02-17, Halozyme Therapeutics(HALO) stock traded between a low of $79.17 and a high of $81.51. Shares are currently priced at $81.01, which is +2.3% above the low and -0.6% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 620.98K, against a daily average of 2.17M.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $82.22 at its peak.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $82.22 at its peak.

HALO News

Simply Wall St 5d
Halozyme Biotech Acquisitions And M&A Plan Weigh On Valuation Case

Halozyme Therapeutics (NasdaqGS:HALO) has acquired three biotech startups as part of a broader push to expand its business. The company highlighted these trans...

Halozyme Biotech Acquisitions And M&A Plan Weigh On Valuation Case
Simply Wall St 7d
Why Halozyme Therapeutics Is Up 8.1% After Raising 2026 Revenue Guidance to up to $1.81 Billion

In January 2026, Halozyme Therapeutics raised its 2026 total revenue guidance to a range of US$1.71 billion to US$1.81 billion, up from its prior outlook of US$...

Why Halozyme Therapeutics Is Up 8.1% After Raising 2026 Revenue Guidance to up to $1.81 Billion

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.